Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
08/15/2022 | 57.3% | HC Wainwright & Co. | $73 → $54 | Maintains | Buy |
01/31/2022 | 112.64% | HC Wainwright & Co. | $75 → $73 | Maintains | Buy |
01/18/2022 | 118.47% | HC Wainwright & Co. | $82 → $75 | Maintains | Buy |
07/28/2021 | 138.86% | HC Wainwright & Co. | $80 → $82 | Maintains | Buy |
06/02/2021 | 133.03% | HC Wainwright & Co. | $81 → $80 | Maintains | Buy |
02/01/2021 | 135.95% | HC Wainwright & Co. | $80 → $81 | Maintains | Buy |
11/23/2020 | 133.03% | HC Wainwright & Co. | $82 → $80 | Maintains | Buy |
07/27/2020 | 138.86% | HC Wainwright & Co. | $96 → $82 | Maintains | Buy |
05/21/2020 | 179.64% | HC Wainwright & Co. | $94 → $96 | Reiterates | → Buy |
02/04/2020 | 173.81% | HC Wainwright & Co. | $110 → $94 | Maintains | Buy |
03/12/2018 | 261.2% | HC Wainwright & Co. | → $124 | Initiates Coverage On | → Buy |
Taro Pharmaceutical Indus Questions & Answers
The latest price target for Taro Pharmaceutical Indus (NYSE: TARO) was reported by HC Wainwright & Co. on August 15, 2022. The analyst firm set a price target for $54.00 expecting TARO to rise to within 12 months (a possible 57.30% upside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for Taro Pharmaceutical Indus (NYSE: TARO) was provided by HC Wainwright & Co., and Taro Pharmaceutical Indus maintained their buy rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Taro Pharmaceutical Indus, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Taro Pharmaceutical Indus was filed on August 15, 2022 so you should expect the next rating to be made available sometime around August 15, 2023.
While ratings are subjective and will change, the latest Taro Pharmaceutical Indus (TARO) rating was a maintained with a price target of $73.00 to $54.00. The current price Taro Pharmaceutical Indus (TARO) is trading at is $34.33, which is out of the analyst's predicted range.